| Date Filed | Type | Description |
| 10/04/2023 |
SC 13G/A
| Flynn James E reports a 0% stake in Terns Pharmaceuticals, Inc. |
| 10/04/2023 |
SC 13G/A
| Flynn James E reports a 0% stake in Evolus, Inc. |
| 08/14/2023 |
SC 13G/A
| Flynn James E reports a 7.4% stake in Singular Genomics Systems, Inc. |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2023 |
4
| Flynn James E (10% Owner) has filed a Form 4 on Nuvalent, Inc.|
Txns:
| Granted 15,000 options to buy
@ $44.68, valued at
$670.2k
|
|
| 06/12/2023 |
4
| Flynn James E (10% Owner) has filed a Form 4 on CareMax, Inc.|
Txns:
| Granted 33,750 options to buy
@ $0 |
|
| 06/09/2023 |
SC 13G/A
| Flynn James E reports a 4.9% stake in GeneDX Holdings Corp. |
| 05/26/2023 |
SC 13G
| Flynn James E reports a 5.9% stake in Cabaletta Bio, Inc. |
| 05/23/2023 |
SC 13D/A
| Flynn James E reports a 4.9% stake in CalciMedica, Inc. |
| 05/18/2023 |
SC 13G
| Flynn James E reports a 5.5% stake in Amedisys, Inc. |
| 05/11/2023 |
4
| Flynn James E (10% Owner) has filed a Form 4 on Larimar Therapeutics, Inc.|
Txns:
| Granted 8,300 options to buy
@ $5.09, valued at
$42.2k
|
|
| 05/10/2023 |
SC 13G/A
| Flynn James E reports a 0% stake in Rain Oncology Inc. |
| 05/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/06/2023 |
SC 13G
| Flynn James E reports a 5.5% stake in Owens & Minor, Inc. |
| 03/28/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/27/2023 |
SC 13D/A
| Flynn James E reports a 24.5% stake in CalciMedica, Inc. |
| 03/22/2023 |
SC 13G
| Flynn James E reports a 6.1% stake in Deciphera Pharmaceuticals, Inc. |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 39.2% stake in Nuvalent, Inc. |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 5.7% stake in AdaptHealth Corp. |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 9.1% stake in Singular Genomics Systems, Inc. |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 1.8% stake in Peak Bio, Inc. |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 0% stake in Turmeric Acquisition Corp. |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 2.5% stake in Orchard Therapeutics plc |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 0% stake in Organogenesis Holdings Inc. |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 3.6% stake in Kura Oncology, Inc. |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 0% stake in Inozyme Pharma, Inc. |
| 02/10/2023 |
SC 13G/A
| Flynn James E reports a 6.2% stake in Edgewise Therapeutics, Inc. |
|